Validation of Novel Continuous Live-Cell Assays for Immune Cell Activation and Killing of Blood Cell Cancers

The blood cancers leukaemia, lymphoma and myeloma are expected to cause the deaths of 56,840 people in the US in 2020. New immunological approaches afford great promise for improved therapies. Here, we describe novel high throughput live-cell image-based assays for immune cell activation and killing of blood cancer cells that are geared towards screening for new treatments for these malignancies. 

The data examples illustrate how continuous live-cell analysis can be used with suspension cells, to provide both additional biological insight (full time-courses, clustering information, morphology) and enhanced productivity (automation, miniaturisation) compared to other techniques.

Download the poster to learn how this approach will be a valuable addition to the technology toolbox for academic and industrial immuno-oncology researchers.

Learn more about Sartorius solutions for CAR-T Discovery & Development at www.sartorius.com/car-t-research.